Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations

Caroline S. Myers, Eli Williams, Carlos Barrionuevo Cornejo, Georgios Pongas, Ngoc L. Toomey, Jose A. Sanches, Maxime Battistella, Samuel Mo, Melissa Pulitzer, Cristopher A. Moskaluk, Govind Bhagat, Kenneth Ofori, Jonathan J. Davick, Octavio Servitje, Denis Miyashiro, Fina Climent, Kimberley Ringbloom, Daniela Duenas, Calvin Law, Sandro Casavilca ZambranoLuis Malpica, Brady E. Beltran, Denisse Castro, Luciana Barreto, Carlos Brites, Jennifer R. Chapman, Jaehyuk Choi, Alejandro A. Gru*, Juan C. Ramos

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations

Abstract

Adult T-cell leukemia-lymphoma (ATLL) is an aggressive malignancy driven by human T-cell leukemia virus type 1 (HTLV-1). Although patients from the Western hemisphere (Afro-Caribbean and South American) face worse prognoses, our understanding of ATLL molecular drivers derives mostly from Japanese studies. We performed multi-omic analyses to elucidate the genomic landscape of ATLL in Western cohorts. Recurrent deletions and/or damaging mutations involving FOXO3, ANKRD11, DGKZ, and PTPN6 implicate these genes as potential tumor suppressors. RNA-sequencing, published functional data and in vitro assays support the roles of ANKRD11 and FOXO3 as regulators of T-cell proliferation and apoptosis in ATLL, respectively. Survival data suggest that ANKRD11 mutation may confer a worse prognosis. Japanese and Western cohorts, in addition to acute and lymphomatous subtypes, demonstrated distinct molecular patterns. GATA3 deletion was associated with chronic cases with unfavorable outcomes. IRF4 and CARD11 mutations frequently emerged in relapses after interferon therapy. Our findings reveal novel putative ATLL driver genes and clinically relevant differences between Japanese and Western ATLL patients.

Original languageEnglish (US)
Pages (from-to)4021-4039
Number of pages19
JournalHaematologica
Volume109
Issue number12
DOIs
StatePublished - Dec 2024

Funding

We acknowledge the patients who consented to inclusion in this study, Admera Health, the University of Virginia Comprehensive Cancer Center, the University of Miami Sylvester Comprehensive Cancer Center and its Flow Cytometry Shared Resource and data analysis by Patricia Guevara, and the Northwestern University Flow Cytometry Core and Research Computing Services for their invaluable contributions. JC was supported in part by the National Institutes of Health (R01CA260064-01A1), the Bakewell Foundation and the Leukemia and Lymphoma Society grant 1377-21. JCR was supported in part by the National Institutes of Health/National Cancer Institute (R01CA223232) and the University of Miami-Sylvester Comprehensive Cancer Center (P30CA240139). CSM was supported by the Monticello College Foundation Olin Fellowship. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. JC was supported in part by the National Institutes of Health (R01CA260064-01A1), the Bakewell Foundation and the Leukemia and Lymphoma Society grant 1377-21. JCR was supported in part by the National Institutes of Health/National Cancer Institute (R01CA223232) and the University of Miami-Sylvester Comprehensive Cancer Center (P30CA240139). CSM was supported by the Monticello College Foundation Olin Fellowship. The content of this paper is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Distinctive genomic features of human T-lymphotropic virus type 1-related adult T-cell leukemia-lymphoma in Western populations'. Together they form a unique fingerprint.

Cite this